Literature DB >> 343344

Serum antibody titers in treatment with trimethoprim-sulfamethoxazole for chronic prostatitis.

E M Meares.   

Abstract

A comparative study of the clinical, bacteriologic, and serum antibody titer response of 22 men who received therapy with trimethoprim-sulfamethoxazole for chronic prostatitis due to various strains of Escherichia coli was done. Of the 7 patients who were cured by therapy on the basis of clinical and bacteriologic data, 6 of 6 patients who had elevated serum antibody titers prior to treatment demonstrated a decrease to normal range of serum titers during follow-up, confirming disappearance of the bacterial antigen. Of the 15 patients who were not cured on the basis of clinical and bacteriologic data, 12 of 12 patients who had elevated serum antibody titers prior to treatment demonstrated no change in serum titers throughout the study, confirming persistence of the bacterial antigen.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 343344     DOI: 10.1016/0090-4295(78)90093-6

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  5 in total

Review 1.  The role of quinolones in the treatment of chronic bacterial prostatitis.

Authors:  K G Naber
Journal:  Infection       Date:  1991       Impact factor: 3.553

2.  Acute and chronic bacterial prostatitis due to E. coli. Description of an animal model.

Authors:  C Jantos; M Altmannsberger; W Weidner; H G Schiefer
Journal:  Urol Res       Date:  1990

3.  Use of a solid-phase radioimmunoassay and formalin-fixed whole bacterial antigen in the detection of antigen-specific immunoglobulin in prostatic fluid.

Authors:  L M Shortliffe; N Wehner; T A Stamey
Journal:  J Clin Invest       Date:  1981-03       Impact factor: 14.808

Review 4.  Chronic bacterial prostatitis: theoretical and experimental considerations.

Authors:  P O Madsen; K M Jensen; P Iversen
Journal:  Urol Res       Date:  1983

Review 5.  Prostatitis.

Authors:  T A Stamey
Journal:  J R Soc Med       Date:  1981-01       Impact factor: 18.000

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.